These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 9095576

  • 1. Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion.
    Nakagawa Y.
    Keio J Med; 1997 Mar; 46(1):1-9. PubMed ID: 9095576
    [Abstract] [Full Text] [Related]

  • 2. Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid.
    Nakagawa Y, Ahmed M, Hall SL, Deganello S, Coe FL.
    J Clin Invest; 1987 Jun; 79(6):1782-7. PubMed ID: 3584470
    [Abstract] [Full Text] [Related]

  • 3. Characterization of Ca(2+)-binding sites in the kidney stone inhibitor glycoprotein nephrocalcin using vanadyl ions: different metal binding properties in strong and weak inhibitor proteins revealed by EPR and ENDOR.
    Mustafi D, Nakagawa Y.
    Biochemistry; 1996 Nov 26; 35(47):14703-9. PubMed ID: 8942630
    [Abstract] [Full Text] [Related]

  • 4. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis.
    Coe FL, Nakagawa Y, Asplin J, Parks JH.
    Miner Electrolyte Metab; 1994 Nov 26; 20(6):378-84. PubMed ID: 7783700
    [Abstract] [Full Text] [Related]

  • 5. Defective urinary crystallization inhibition and urinary stone formation.
    Carvalho M, Lulich JP, Osborne CA, Nakagawa Y.
    Int Braz J Urol; 2006 Nov 26; 32(3):342-8; discussion 349. PubMed ID: 16813682
    [Abstract] [Full Text] [Related]

  • 6. Nephrocalcin in patients with renal cell carcinoma.
    Nakagawa Y, Netzer M, Michaels EK, Suzuki F, Ito H.
    J Urol; 1994 Jul 26; 152(1):29-34. PubMed ID: 8201680
    [Abstract] [Full Text] [Related]

  • 7. Kidney stone inhibitors in patients with renal stones and endemic renal tubular acidosis in northeast Thailand.
    Nakagawa Y, Carvalho M, Malasit P, Nimmannit S, Sritippaywan S, Vasuvattakul S, Chutipongtanate S, Chaowagul V, Nilwarangkur S.
    Urol Res; 2004 May 26; 32(2):112-6. PubMed ID: 14758448
    [Abstract] [Full Text] [Related]

  • 8. Nephrocalcin: biosynthesis by human renal carcinoma cells in vitro and in vivo.
    Nakagawa Y, Sirivongs D, Novy MB, Netzer MF, Michaels E, Vogelzang NJ, Coe FL.
    Cancer Res; 1992 Mar 15; 52(6):1573-9. PubMed ID: 1540966
    [Abstract] [Full Text] [Related]

  • 9. Urinary calcium oxalate crystal growth inhibitors.
    Worcester EM.
    J Am Soc Nephrol; 1994 Nov 15; 5(5 Suppl 1):S46-53. PubMed ID: 7873744
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins.
    Hess B, Nakagawa Y, Coe FL.
    Am J Physiol; 1989 Jul 15; 257(1 Pt 2):F99-106. PubMed ID: 2750929
    [Abstract] [Full Text] [Related]

  • 11. Elucidation of multiple forms of nephrocalcin by 31P-NMR spectrometer.
    Nakagawa Y, Otsuki T, Coe FL.
    FEBS Lett; 1989 Jul 03; 250(2):187-90. PubMed ID: 2753126
    [Abstract] [Full Text] [Related]

  • 12. Modulatory effect of the 23-kD calcium oxalate monohydrate binding protein on calcium oxalate stone formation during oxalate stress.
    Asokan D, Kalaiselvi P, Varalakshmi P.
    Nephron Physiol; 2004 Jul 03; 97(1):p23-30. PubMed ID: 15153748
    [Abstract] [Full Text] [Related]

  • 13. Characterization of calcium-binding sites in the kidney stone inhibitor glycoprotein nephrocalcin with vanadyl ions: electron paramagnetic resonance and electron nuclear double resonance spectroscopy.
    Mustafi D, Nakagawa Y.
    Proc Natl Acad Sci U S A; 1994 Nov 22; 91(24):11323-7. PubMed ID: 7972057
    [Abstract] [Full Text] [Related]

  • 14. Inhibitors within the nephron.
    Coe FL, Nakagawa Y, Parks JH.
    Am J Kidney Dis; 1991 Apr 22; 17(4):407-13. PubMed ID: 2008908
    [Abstract] [Full Text] [Related]

  • 15. Evidence that mouse renal proximal tubule cells produce nephrocalcin.
    Sirivongs D, Nakagawa Y, Vishny WK, Favus MJ, Coe FL.
    Am J Physiol; 1989 Sep 22; 257(3 Pt 2):F390-8. PubMed ID: 2782421
    [Abstract] [Full Text] [Related]

  • 16. Glycoprotein calcium oxalate crystal growth inhibitor in urine.
    Worcester EM, Nakagawa Y, Coe FL.
    Miner Electrolyte Metab; 1987 Sep 22; 13(4):267-72. PubMed ID: 3306319
    [Abstract] [Full Text] [Related]

  • 17. Protein inhibitors of crystal growth.
    Kaiser ET, Bock SC.
    J Urol; 1989 Mar 22; 141(3 Pt 2):750-2. PubMed ID: 2645434
    [Abstract] [Full Text] [Related]

  • 18. Isolation and purification of a new glycoprotein from human urine inhibiting calcium oxalate crystallization.
    Atmani F, Lacour B, Drüeke T, Daudon M.
    Urol Res; 1993 Jan 22; 21(1):61-6. PubMed ID: 8456540
    [Abstract] [Full Text] [Related]

  • 19. The role of Tamm-Horsfall glycoprotein and Nephrocalcin in calcium oxalate monohydrate crystallization processes.
    Hess B.
    Scanning Microsc; 1991 Sep 22; 5(3):689-95; discussion 696. PubMed ID: 1808706
    [Abstract] [Full Text] [Related]

  • 20. Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis.
    Nakagawa Y, Abram V, Parks JH, Lau HS, Kawooya JK, Coe FL.
    J Clin Invest; 1985 Oct 22; 76(4):1455-62. PubMed ID: 4056037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.